Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL – Cancer Network

Thought leader detailed the findings from an oral presentation investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork about the findings from an oral presentation investigating the prognostic value of circulating tumor DNA among patients with diffuse large B cell lymphoma (DLBCL) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

What we found is that about a quarter of patients had detectable minimal residual disease [MRD] in their apheresis stem cell product, and those patients had much worse outcomes. The 5-year progression-free survival for that cohort of patients, the MRD-positive patients, was only 13% compared with 52% for MRD-negative patients. And as you would expect, the bad outcomes in those patients were driven by high rates of relapse after transplant. Those patients also had inferior progression-free survival. I think those results suggest that the quarter of patients or so who are MRD positive should receive an alternative treatment because they really dont do well with autologous stem cell transplantation.

And then the other cohort that we analyzed was patients who had peripheral blood samples collected serially after transplant. And in that sample, we found that a positive MRD assessment in plasma with fairly high sensitivity and specificity could predict patients who were about to relapse with a median lead time of about 2 months. Again, I think one could think about using these data to support a clinical trial where patients have serial samples that have to be fairly frequent, serial samples collected after transplant, with the idea being that you might be able to preemptively treat some of these patients before they have clinical relapse.

More here:
Reid Merryman, MD, on Study Findings Investigating Prognostic Value of ctDNA for Patients with DLBCL - Cancer Network

Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy – InvestorIntel

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemixs patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. I have come across some good technologies and put together a team that have succeeded, Thomas commented.

Thomas also provided an update on Hemostemixs ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patients own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.

To watch the full interview,click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

OnOctober 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

Go here to see the original:
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy - InvestorIntel

Covid-19 Impact On Stem Cell Therapy Market 2020 Huge Potential in Future Growth by 2027 | Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc.,…

A new market study on the 2020-2027Stem Cell Therapy Marketwith 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry-validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for the 2020-2027 Stem Cell Therapy Market Forecast till2027*.

Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry @https://www.coherentmarketinsights.com/insight/request-sample/2848

Major Market Top Key Players: Stem Cell Therapy market

Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Regional Analysis:

North America: United States, Canada, Mexico

Europe: Germany, France, UK, Russia, Italy, Rest of Europe

Middle East Africa: Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa

Asia-Pacific: India, Australia, Japan, China, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

In the end, the report makes some important proposals for a new project of this Industry before evaluating its feasibility. Overall, the report provides an in-depth insight into the global Stem Cell Therapy industry covering all important parameters.

Request for Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2848

Further, in the research report, the following points are included along with an in-depth study of each point:

Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered.

Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.

Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Other analyses Apart from the information, trade and distribution analysis for the Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

In continuation with this data, the sale price is for various types, applications and regions are also included. The Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Few Necessary Concerns Covered In The Report:

Innovation Techniques enlisted for the development in the market.

The main Regions considered profitable for Market development.

Development techniques implemented by key players.

The Prediction of the expected growth rate of market size and market share.

Apply Promo Code STAYHOME and Get Instant Discount of USD 1000

If you purchase the report this year:

Flat20%instant discount

25%discount on 2nd report

15 %free customization

Buy This Complete A Business Report @: https://www.coherentmarketinsights.com/insight/buy-now/2848

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?

Which are the key factors driving the Stem Cell Therapy market?

What was the size of the emerging Stem Cell Therapy market by value in 2020?

What will be the size of the emerging Stem Cell Therapy market in 2027?

Which region is expected to hold the highest market share in the Stem Cell Therapy market?

What trends, challenges and barriers will impact the development and sizing of the Global Stem Cell Therapy market?

What is sales volume, revenue, and price analysis of top manufacturers of Stem Cell Therapy market?

What are the Stem Cell Therapy market opportunities and threats faced by the vendors in the global Stem Cell Therapy Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Stem Cell Therapy market in the near future.

Thanks for reading this article you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 Email: sales@coherentmarketinsights.comWeb:https://www.coherentmarketinsights.com

More:
Covid-19 Impact On Stem Cell Therapy Market 2020 Huge Potential in Future Growth by 2027 | Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc.,...

Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex…

The Adipose Derived Stem Cell Therapy Market Research Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements. The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, theAdipose Derived Stem Cell Therapy market report analyses and provides historic data along with the current performance of the market

Adipose derived stem cells (ADSCs) are stem cells derived from adipocytes, and can differentiate into variety of cell types. ADSCs have multipotency similar to bone marrow mesenchymal stem cells, thus ADSCs substitute for bone marrow as a source of stem cells. Numerous manual and automatic stem cell separation procedures are adopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can also be used to isolate ADSCs from other stem cells within a cell solution.

This Press Release will help you to Know the Volume, growth with Impacting Trends. Get SAMPLE PDF (Including Full TOC, Table & Figures) at:

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

Global Adipose Derived Stem Cell Therapy Market competition by Top Key Players: BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

Adipose Derived Stem Cell Therapy Market section by Region:

The Middle East and Africa North America South America Europe Asia-Pacific

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Adipose Derived Stem Cell Therapy market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Adipose Derived Stem Cell Therapy global market and its growth potential in the years to come.

TheAdipose Derived Stem Cell TherapyMarket report offers a plethora of insights which include:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2357

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the Adipose Derived Stem Cell Therapy Market Successful market entry strategies formulated by emerging market players Pricing and marketing strategies adopted by established market players Country-wise assessment of the Adipose Derived Stem Cell Therapy Market in key regions Year-on-Year growth of each market segment over the forecast period 2026

TheAdipose Derived Stem Cell TherapyMarket report considers the following years to predict market growth:

The GlobalAdipose Derived Stem Cell TherapyMarket is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities Chapter 2: Market Competition by Manufacturers Chapter 3: Production by Regions Chapter 4: Consumption by Regions Chapter 5: Production, By Types, Revenue and Market share by Types Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications Chapter 7: Complete profiling and analysis of Manufacturers Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers Chapter 10: Marketing Strategy Analysis, Distributors/Traders Chapter 11: Market Effect Factors Analysis Chapter 12: Market Forecast Chapter 13:Adipose Derived Stem Cell Therapy Research Findings and Conclusion, Appendix, methodology and data source

Read the original here:
Adipose Derived Stem Cell Therapy Market Analysis and Forecast, 2020-2026 Coherent Market Insights | BioRestorative Therapies, Inc., Celltex...

New COVID-19 Treatment Uses Stem Cells – Freethink

Stem cells found in the umbilical cords of newborn babies may provide life-saving care for people with a serious case of coronavirus.

These kinds of cells have a remarkable capacity to self-renew and regenerate damaged tissue, making them a prime candidate for healing respiratory systems.

A team at the University of Miami enlisted 24 patients who were hospitalized at the Jackson Memorial Hospital. All of them had developed severe acute respiratory distress syndrome after contracting COVID-19.

In the double-blind study, the patients and even the doctors didn't know if they were delivering an infusion of mesenchymal stem cells or a placebo. Each patient received two infusions, just days apart. After the infusion with over 200 million stem cells, the cells migrated naturally to the lungs.

"(The umbilical cord) is a unique resource of cells that are under investigation for their possible use in cell therapy applications, anytime you have to modulate immune response or inflammatory response," said study lead Camillo Ricordi, adding that a single umbilical cord can provide enough doses to help over 10,000 patients.

"We've been studying them with our collaborators in China for more than 10 years in Type 1 Diabetes, and there are currently over 260 clinical studies listed in clinicaltrials.gov for treatment of other autoimmune diseases."

In this small study, the team found that the stem cell infusions could greatly reduce the risk of death and hasten recovery time, even for patients with severe cases of COVID-19.

One month after the COVID treatment, the survival rate was 91% for those who received the stem cell treatment, versus 42% for people who got the placebo. Every patient younger than 85 years old who received the stem cell treatment survived at one month.

Recovery time was also quicker for those who received the treatment with more than half going home from the hospital less than two weeks after the second infusion. Their work is published in STEM CELLS Translational Medicine.

The researchers were impressed with how well the treatment worked.

Camillo Ricordi, M.D., director of the Diabetes Research Institute (DRI) and Cell Transplant Center at the University of Miami Miller School of Medicine. Credit: Image by University of Miami Health System

"It's like smart bomb technology in the lung to restore normal immune response and reverse life-threatening complications," said Ricordi.

When the pandemic set in, Ricordi asked collaborators in China if they had looked into stem cell research for coronavirus they had, and often with success. But Ricordi wanted to take the research up a notch by ensuring the study was randomized, and there was a control group (receiving a placebo) with which to compare results.

In the future, Ricordi would like to study if stem cells could help COVID-19 patients before they become severely ill, possibly slowing the disease's progression.

We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [emailprotected]

Read this article:
New COVID-19 Treatment Uses Stem Cells - Freethink

Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative…

PHOENIX, Jan. 12, 2021 /PRNewswire/ --(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to initiate the first clinical trial using cellular immunotherapy for treatment of stroke. The proposed study will involve treatment of 4 groups of 8 patients per group. Treated patients will receive one intravenous injection of ImmCelZ product at 0.5 X10(6) cells per kilogram; the second arm 1 X10(6) cells per kilogram; the third arm 2X10(6) cells per kilogram; and the fourth arm will serve as a control. Patients will be followed for a total of 6 months with both safety and efficacy being examined.

"The uniqueness of the ImmCelz approach is that the immunological cells used are derived from the same patient to which they are administered." Said Dr. Amit Patel, board member of the Company and co-inventor of the technology. "We have previously reported potent reduction of stroke infarct volume, as well as post-stroke behavioral improvements in animals treated with ImmCelz. We are enthusiastic to move this treatment into patients, with stroke being the first indication."

The ImmCelz treatment involves utilization of stem cells outside of the body to "reprogram" the patient's own immune cells so as to endow upon the immune cells regenerative activities. In contrast to other stem cell based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged brain and induce regeneration.

"Utilization of ex vivo manipulation of immune cells to induce biologically relevant therapeutic cascades was originally performed by experiments 17 years ago with our colleague Dr. Wei-Ping Min, in which we utilized dendritic cells to induce a population of T cells that would protect organ transplant regeneration1." Said Dr. Thomas Ichim, co-inventor of ImmCelz. "We are enthusiastic that these technologies are now maturing to the point of entering clinical trials and actually helping patients."

"According to the National Institute of Health (NIH), Stroke affects approximately 800,000 people in the United States annually alone. Very little treatments are available subsequent to initiation of brain damage." Said Timothy Warbington, President and CEO of the Company. "Based on our previous experiences with the FDA, we anticipate a smooth review process given the fact that the active ingredient in ImmCelz are cells from the same patient. Subsequent to the first IND clearance, we plan to file IND's on other indications, which appear promising based on preclinical data."

About Creative Medical Technology Holdings Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in Regenerative Medicine in the fields of immunotherapy, urology, neurology and orthopedics and is quoted on the OTC under the ticker symbol CELZ. For further information about the company, please visitwww.creativemedicaltechnology.com.

Forward Looking Statements OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website atwww.sec.gov.

Creativemedicaltechnology.com http://www.StemSpine.com http://www.Caverstem.com http://www.Femcelz.com

1Inhibitory Feedback Loop Between Tolerogenic Dendritic Cells and Regulatory T Cells in Transplant Tolerance | The Journal of Immunology (jimmunol.org)

SOURCE Creative Medical Technology Holdings, Inc.

Home

Excerpt from:
Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz Regenerative...

Global Cell Freezing Media for Cell Therapy Market 2020 Dynamics Analysis, Size Witness Growth Acceleration During 2025 – KSU | The Sentinel Newspaper

A collective analysis report titled Global Cell Freezing Media for Cell Therapy Market Growth 2020-2025 analyzes the market status and outlook from the view of players, countries, product types, and end industries. The report offers an exhaustive study based on current trends influencing this vertical throughout assorted geographies. The report provides a product overview and highlights of product and application segments of the market including price, revenue, sales growth rate, and market share by product. It presents comprehensive data that enhances the understanding, scope, and application of this global Cell Freezing Media for Cell Therapy report. The report also explores the current outlook in global and key regions from the perspective of players, countries, product types, and end industries.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

More Trending Topics From Business Insights:

A comprehensive analysis of the competitive manufacturers, as well as the new entrants, is given along with their brief research. This report is specially designed to know accurate market insights and market status. The report studies the contestant performance of the global Cell Freezing Media for Cell Therapy market. Furthermore, the report encompasses details regarding the market share attained by these application segments along with their potential and consumption volume during the study period from 2015 to 2025. The market research report classifies the competitive spectrum of this industry in elaborate detail. Additionally, the major steps taken by key players to address the business challenges put forward are discussed in the report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/137947

Primitive vendors included in the market are:

The region-wise study of the global Cell Freezing Media for Cell Therapy market unfolds important regions like:

In market segmentation by types, the report covers:

In market segmentation by applications, the report covers the following uses:

Sales Forecast:

The report supplies historical revenue and volume that backing information about the market capacity, and it helps to evaluate numbers for key areas in the global Cell Freezing Media for Cell Therapy market. The study includes a share of each segment of the market combined with methodical information about types and applications of the market. This report delivers a forward-looking prospect of various factors driving or restraining market growth.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/137947/global-cell-freezing-media-for-cell-therapy-market-growth-2020-2025

Reasons For Buying This Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: sales@marketsandresearch.biz Web: http://www.marketsandresearch.biz

Follow this link:
Global Cell Freezing Media for Cell Therapy Market 2020 Dynamics Analysis, Size Witness Growth Acceleration During 2025 - KSU | The Sentinel Newspaper

Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and…

Jan. 11, 2021 20:00 UTC

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd.. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), which is being held virtually from February 812, 2021.

The international, multi-center, randomized Phase 3 study for omidubicel evaluated the safety and efficacy of omidubicel in patients with hematologic malignancies undergoing allogeneic bone marrow transplant compared to a comparator group of patients who received a standard umbilical cord blood transplant.

This will be the first presentation of the full efficacy and safety results of this study. Gamida Cell previously reported in 2020 top-line data for omidubicel, an advanced cell therapy under development as a potentially life-saving allogeneic hematopoietic stem cell transplant solution for patients with hematologic malignancies. Last May, Gamida Cell reported that the study achieved its primary endpoint, demonstrating a highly statistically significant reduction in time to neutrophil engraftment, a key milestone in a patients recovery from a bone marrow transplant. Last October, the company reported that the omidubicel phase 3 study achieved its secondary endpoints of platelet engraftment, infections, and hospitalizations.

Details about the presentation are as follows: Title: Improved Clinical Outcomes with Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized, Multicenter Study Lead Author: Mitchell E. Horwitz, M.D. Time: Tuesday, February 9, 2021, 4:45-5:00 p.m. EST

About Omidubicel

Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). In both Phase 1/2 and Phase 3 clinical studies (NCT01816230, NCT02730299), omidubicel demonstrated rapid and durable time to engraftment and was generally well tolerated. The company expects to submit a full biologics licensing application to the U.S. FDA in the second half of 2021. Omidubicel is also being evaluated in a Phase 1/2 clinical study in patients with severe aplastic anemia (NCT03173937). The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn, which is the same investigational development candidate as omidubicel. For more information on clinical trials of omidubicel, please visit http://www.clinicaltrials.gov.

Omidubicel is an investigational therapy, and its safety and efficacy have not been established by the U.S. Food and Drug Administration or any other health authority.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit http://www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of and data reported from the clinical trials of Gamida Cells product candidates, anticipated regulatory filings, launch readiness and FDA approval, commercialization efforts and Gamida Cells expectations regarding its projected ongoing operating activities, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Gamida Cells clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cells Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on February 26, 2020 and its Report on Form 6-K furnished to the SEC on August 12, 2020, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cells actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005371/en/

The rest is here:
Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and...

Cate Dyer of StemExpress is Named Businesswoman of the Year! – PRNewswire

SACRAMENTO, Calif., Jan. 12, 2021 /PRNewswire/ --The Sacramento Metropolitan Chamber of Commerce announced it will name Cate Dyer, CEO of StemExpress, the "Businesswoman of the Year" at their 126th Annual Business Awards. Since 1895, Metro Chamber has recognized Sacramento's most esteemed players in the business community. The 2021 Annual Dinner and Business Awards will be held virtually for the first time, and Ms. Dyer will receive this extraordinary honor on February 5th, 2021.

Ms. Dyer founded StemExpress in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. StemExpress supports medical research, clinical trials, commercialization of disease specific treatment, cell and gene therapies, precision and regenerative medicine, as well as researchers and clinicians from all around the world who are developing new treatments and cures. StemExpress has a network of healthcare partnerships that includes over 50 hospitals in Europe as well as three (3) US healthcare systems that encompasses 31 hospitals, 35 outpatient facilities and 20 individual practices. StemExpress is currently the nation's leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. StemExpress is registered with the U.S. Food and Drug Administration (FDA) and has seven (7) independently owned and operated brick-and mortar cellular clinics across the United States to collect blood, cells and tissue from patients and donors. These clinics include state-of-the-art cell manufacturing laboratories for clinical and research purposes, and CLIA certified/high-complexity diagnostics.

Since inception, StemExpress has been committed to transformative, positive impacts on the community. In line with this commitment, StemExpress immediately recognized the unparalleled challenges the COVID-19 virus presented to its communities, healthcare entities, local businesses, and the economy at large. In a matter of weeks, the company built out a seamless, end-to-end COVID-19 testing solution, all while continuing to grow its core cellular business. This end-to-end solution includes on-line patient registration, scheduling, specimen collection, pop-up site management, and laboratory testing using gold-standard PCR testing at high-volume capacity with rapid turn-around times. StemExpress directly and proudly supports frontline workers, inner city communities, hospitals, skilled nursing facilities, school districts, correctional facilities, utility companies, major league sports, tribal territories and territorial governments, among others. Through public health partnerships, StemExpress has also provided free testing services to vulnerable members of the community, including the uninsured and other under-represented populations.

The 2021 Annual Business Awards will pay tribute to Cate Dyer's extraordinary effort to support Sacramento's communities, businesses, and the heroes who keep our economy moving.

Contact: [emailprotected]

SOURCE StemExpress

https://www.stemexpress.com

Read the rest here:
Cate Dyer of StemExpress is Named Businesswoman of the Year! - PRNewswire

Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes – Business Wire

LYON, France--(BUSINESS WIRE)--Regulatory News:

Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced today it is developing a hydrogel scaffold that hosts and protects pancreatic cells for replacement of the missing cells of people with type 1 diabetes.

Capitalizing on our expertise in regenerative medicine and diabetes, our multidisciplinary team has developed a scaffold for cells with the aim of being transformed into an organoid controlling glycemia. The collaboration with the team of experts of Professor Pattou has created great momentum and the first results obtained in small animals are really exciting, said Olivier Soula, Deputy CEO and Director of R&D.

Among the 25 million people with type 1 diabetes in the world, and despite intensive and sophisticated insulin treatments, some patients diabetes are uncontrolled and should require pancreatic cell therapy to survive.

Cell therapy consists of the administration of living cells to diabetic patients to restore glycemic control. Since the 1980s, it has been possible to transplant Langerhans islets taken from the pancreas of a deceased donor. However, despite health authorities approval, this technique is restricted to a very limited population due to remaining issues:

To solve these issues, Adocia has designed a new type of hydrogel scaffold able to host transplanted cells allowing them to release insulin while protecting them from immune reaction.

We are on our way to achieving a patient dream, that cell therapy would provide benefit to a large population without requiring immunosuppressant drugs, which is a major drawback today for its use, commented Gerard Soula, President & CEO of Adocia.

The program has been initiated with human Langerhans islet to achieve the proof of concept of a safe and effective implant, that is easily implantable. The next step is to extend the application to stem cells avoiding strong limitation of the limited number of donors.

Academic collaboration has been established with the research team of Professor Franois Pattou (DiabInnov, Inserm Lille, France), a worldwide expert in clinical and non-clinical Langerhans islet transplantation. Preliminary results obtained during this collaboration are promising. A first patent is pending.

We strongly believe that cell therapy has a great future for the treatment of Type 1 if the limitations of cadaveric islets source and the need of immunosuppressant drugs can be addressed. Impressive advances have been made over the past few years in the differentiation of human stem cells toward functional insulin secreting cells. So far, immunoisolation devices implanted with insulin secreting cells, proved to be disappointing in clinical trials. The scaffold invented by Adocia offers promising features to overcome this medical challenge. said Professor Franois Pattou, UMR1190 Translational Research for Diabetes Director, INSERM, University Hospital of Lille in France.

Upcoming events

In January, Adocia Members of management will be presenting at the virtual H.C. Wainwright BioConnect 2021 Conference, then will participate in the 24th ODDO BHF Digital Forum and BIO Partnering at JP Morgan. Please, see details and links on the Calendar below:

January 7 -13: ODDO Forum

January 11-14: H.C. Wainwright Conferences

Gerard Soula Presentation at H.C. Wainwright BioConnect 2021 Conference: Date: Monday, January 11th, 2021 Time: 6:00 am EST Link: https://journey.ct.events/view/05d513ad-9333-4971-9eee-1446015ccf34

The H.C. Wainwright webcast will be available on demand starting Monday, January 11th, 2021 at 6:00 Am EST. Replays of the presentation will be available on the Companys website for 90 days following the event.

January 11-15: BioPartnering at JP Morgan

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocias portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring five clinical-stage products and three products in preclinical-stage. Adocia aims to expand its portfolio towards the treatment of other metabolic diseases and their comorbidities. The proprietary BioChaperone technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application.

Adocias clinical pipeline includes four novel insulin formulations for prandial treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo) and one combination of a prandial insulin with amylin analog pramlintide M1Pram. The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.

Adocia preclinical pipeline includes three bi-hormonal products: two combinations of rapid human insulin analogues and Pramlintide (BioChaperone LisPram andBioChaperone AsPram) and a combination of insulin glargine with Liraglutide (BioChaperone GlaLira) for the treatment of diabetes.

Adocia has now added a fourth program in preclinical with the development of a hydrogel scaffold for cell therapy in the treatment of type 1 diabetes. A first patent has been filed.

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the Risk Factors section of the Universal Registration Document filed with the French Autorit des marchs financiers on April 22, 2020 (a copy of which is available at http://www.adocia.com) and to the development of economic conditions financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Adocia to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.

See the original post:
Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes - Business Wire